Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.5K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

610
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
610
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

579
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
579
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

1.2K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.2K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

711
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
711
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

803
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
803

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Damaged myocardium facilitates arrhythmogenesis in a canine model of Brugada syndrome.

Heart rhythm·2026
Same author

Concealed Wolff-Parkinson-White and the road not taken: The story behind "the V-on-H".

Heart rhythm·2025
Same author

Cardiac defibrillation in humans.

Heart rhythm·2025
Same author

Describing cardiac anatomy: The truth is staring us in the face.

Heart rhythm·2024
Same author

Vigorous Exercise in Patients With Congenital Long QT Syndrome: Results of the Prospective, Observational, Multinational LIVE-LQTS Study.

Circulation·2024
Same author

First conclusive evidence that the implantable cardioverter-defibrillator reduces total mortality compared with drugs.

Heart rhythm·2024

Related Experiment Video

Updated: Apr 15, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.2K

Interventional and device-based autonomic modulation in heart failure.

Mark J Shen1, Douglas P Zipes2

  • 1Krannert Institute of Cardiology, Department of Medicine, Indiana University School of Medicine, 1800 North Capitol Avenue, Room E371, Indianapolis, IN 46202, USA.

Heart Failure Clinics
|April 4, 2015
PubMed
Summary
This summary is machine-generated.

Novel neuromodulation therapies show promise for treating heart failure by restoring autonomic balance. These device-based treatments, including spinal cord and vagus nerve stimulation, are safe and effective in early trials.

Keywords:
Autonomic nervous systemBaroreflex activation therapyHeart failureRenal sympathetic nerve denervationSpinal cord stimulationVagus nerve stimulation

More Related Videos

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

7.6K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K

Related Experiment Videos

Last Updated: Apr 15, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.2K
Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

7.6K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K

Area of Science:

  • Cardiology
  • Neurology
  • Biomedical Engineering

Background:

  • Heart failure (HF) is a growing global health concern with significant mortality.
  • Autonomic nervous system imbalance, marked by sympathetic overactivity and parasympathetic underactivity, is a key feature of HF.
  • Current treatments for HF have limitations, highlighting the need for innovative therapeutic approaches.

Purpose of the Study:

  • To review emerging neuromodulatory therapies for heart failure.
  • To discuss the mechanisms and clinical evidence for device-based autonomic balance restoration in HF.
  • To provide an overview of specific neuromodulation techniques.

Main Methods:

  • Review of preclinical studies and early clinical trials on neuromodulation in heart failure.
  • Discussion of various neuromodulatory treatment modalities.
  • Focus on device-based interventions targeting autonomic imbalance.

Main Results:

  • Preclinical and early clinical data indicate the safety and efficacy of neuromodulation in HF.
  • Neuromodulatory therapies aim to correct the sympathetic hyperactivity and parasympathetic hypoactivity seen in HF.
  • Specific therapies reviewed include spinal cord stimulation, vagus nerve stimulation, baroreceptor activation therapy, and renal sympathetic nerve denervation.

Conclusions:

  • Neuromodulation represents a promising therapeutic avenue for heart failure management.
  • Device-based interventions offer a novel approach to restore autonomic balance in HF patients.
  • Further research and clinical trials are warranted to establish the long-term benefits of these therapies.